as 07-04-2025 12:37pm EST
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
Founded: | 2005 | Country: | United States |
Employees: | N/A | City: | SAN MATEO |
Market Cap: | 10.6M | IPO Year: | 2011 |
Target Price: | $6.00 | AVG Volume (30 days): | 42.9K |
Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.44 | EPS Growth: | N/A |
52 Week Low/High: | $0.43 - $1.19 | Next Earning Date: | 08-13-2025 |
Revenue: | $27,000 | Revenue Growth: | -95.85% |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | 14533.26% |
TLPH Breaking Stock News: Dive into TLPH Ticker-Specific Updates for Smart Investing
GuruFocus.com
2 months ago
PR Newswire
2 months ago
PR Newswire
2 months ago
Argus Research
3 months ago
GuruFocus.com
3 months ago
PR Newswire
3 months ago
PR Newswire
3 months ago
PR Newswire
3 months ago
The information presented on this page, "TLPH Talphera Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.